返回 Agenda
Session 6: Pushing Well Forward - Commercialization of Biosimilars Post-2020
Session Chair(s)
Geoff Eich
Executive Director, External Affairs
Amgen Biosimilars, United States
This discussion will focus on the post-2020 U.S. biosimilars market and considerations for sustained biosimilars development of increasingly complex and/or rare disease biologic reference products. Topics will include implications of innovation in biosimilar markets (e.g. treatment of breast and colorectal cancers) and selection of viable reference products for biosimilars development. Panelists will be asked to address important policies and considerations related to the approval, post-market maintenance, healthcare community acceptance and reimbursement of highly complex and/or rare disease biosimilar medicines post-2020.
Speaker(s)
Panelists
Aharon Gal, PhD
Sanford C Bernstein, United States
Senior Research Analyst
Leah Christl, PhD
Amgen, United States
Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy
Steven Kozlowski, MD
FDA, United States
Director, Office of Biotechnology Products, OPQ, CDER